Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1981 1
1982 2
1986 2
1988 1
1989 2
1990 1
1991 2
1992 2
1993 3
1994 3
1995 2
1996 3
1997 1
1998 3
1999 2
2000 1
2001 3
2002 4
2003 6
2004 2
2005 4
2006 13
2007 12
2008 3
2009 7
2010 11
2011 11
2012 14
2013 16
2014 16
2015 12
2016 16
2017 14
2018 22
2019 13
2020 9
2021 6
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Korobelnik JF, et al. Among authors: vitti r. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8. Ophthalmology. 2014. PMID: 25012934 Clinical Trial.

The corresponding proportions of eyes gaining 15 letters were 41.6% and 31.1% versus 7.8% (P < 0.0001) in VISTA, and 32.4% and 33.3% versus 9.1% (P < 0.0001) in VIVID. Similarly, mean reductions in central retinal thickness were 185.9 and 183.1 versus 73.3 mum

…

The corresponding proportions of eyes gaining 15 letters were 41.6% and 31.1% versus 7.8% (P < 0.0001) in VISTA, and 32.4% and 33.

…
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Brown DM, et al. Among authors: vitti r. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. JAMA Ophthalmol. 2021. PMID: 34351414 Free PMC article. Clinical Trial.

At 24 weeks, treatment with aflibercept resulted in a 2-step or greater improvement in DRSS level in 157 of 269 eyes (58.4%) in the combined aflibercept groups vs 8 of 133 eyes (6.0%) in the control group (adjusted difference, 52.3%; 95% CI, 45.2%-59.5%; P < .001). At 5

…
At 24 weeks, treatment with aflibercept resulted in a 2-step or greater improvement in DRSS level in 157 of 269 eyes (58.4%) in the combined …
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Heier JS, et al. Among authors: vitti r. Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17. Ophthalmology. 2016. PMID: 27651226 Clinical Trial.

RESULTS: Mean BCVA gain from baseline to week 148 with IAI 2q4, IAI 2q8, and laser control was 10.4, 10.5, and 1.4 letters (P < 0.0001) in VISTA and 10.3, 11.7, and 1.6 letters (P < 0.0001) in VIVID, respectively. The proportion of eyes that gained 15 letters

…

RESULTS: Mean BCVA gain from baseline to week 148 with IAI 2q4, IAI 2q8, and laser control was 10.4, 10.5, and 1.4 letters (P < 0.

…
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. Among authors: vitti r. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382
The proportion of eyes without fluid in the central subfield with 8-mg vs 2-mg aflibercept was 50.9% (n = 27) vs 34.0% (n = 18) (difference, 17.0 [95% CI, -1.6 to 35.5] percentage points; P = .08) at week 16 and 39.6% (n = 21) vs 28.3% (n = 15) (difference, 11.3 [95% CI, - …
The proportion of eyes without fluid in the central subfield with 8-mg vs 2-mg aflibercept was 50.9% (n = 27) vs 34.0% (n = 18) (difference, …
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.
Brown DM, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, Heier JS; RUBY Investigators. Brown DM, et al. Among authors: vitti r. Retina. 2022 Jun 1;42(6):1111-1120. doi: 10.1097/IAE.0000000000003441. Epub 2022 Feb 22. Retina. 2022. PMID: 35234673 Free PMC article. Clinical Trial.

Central subfield retinal thickness reductions at Week 12 were -169.4, -184.0, and -174.6 m (nominal P = 0.0183, HD combo vs. IAI); Week 36 reductions for LD combo and HD combo q8w and q12w versus IAI were -210.4, -223.4, and -193.7 versus -61.9 m (nominal P < 0.0

…
Central subfield retinal thickness reductions at Week 12 were -169.4, -184.0, and -174.6 m (nominal P = 0.0183, HD combo vs. IAI); We …
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Schmidt-Erfurth U, et al. Among authors: vitti r. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084500 Clinical Trial.

The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of -0.64 [95% CI, -0.89 to -0.40] and -0.55 [95% CI, -0.79 to -0.30]; P < 0.0001, post hoc analysis). Incidences of Antiplatelet Trialists' Collabor

…
The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of -0.64 [95% CI, …
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Among authors: vitti r. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
The difference in least squares means was -0.57 letters (95% CI -2.26 to 1.13, p value for non-inferiority <0.0001) between 8q12 and 2q8 and -1.44 letters (-3.27 to 0.39, p value for non-inferiority 0.0031) between aflibercept 8q16 and 2q8. ...
The difference in least squares means was -0.57 letters (95% CI -2.26 to 1.13, p value for non-inferiority <0.0001) between 8q12 a …
An extended model of phosphorus metabolism in growing ruminants.
Dias RS, López S, Patiño RM, Silva TS, Silva Filho JC, Vitti DM, Peçanha MR, Kebreab E, France J. Dias RS, et al. Among authors: vitti dm. J Anim Sci. 2011 Dec;89(12):4151-62. doi: 10.2527/jas.2010-3669. Epub 2011 Jul 15. J Anim Sci. 2011. PMID: 21764835

Increased P intake positively affected total P (r = 0.97, P < 0.01) and endogenous P excretion in feces (r = 0.85, P < 0.01), P flow from plasma to saliva (r = 0.73, P < 0.01), from saliva to rumen (r = 0.73, P <

…

Increased P intake positively affected total P (r = 0.97, P < 0.01) and endogenous P excretion in feces (r =

…
Effects of phosphorus intake on phosphorus flow in growing pigs: application and comparison of two models.
Schulin-Zeuthen M, Lopes JB, Kebreab E, Vitti DM, Abdalla AL, Haddad MD, Crompton LA, France J. Schulin-Zeuthen M, et al. Among authors: vitti dm. J Theor Biol. 2005 Sep 21;236(2):115-25. doi: 10.1016/j.jtbi.2005.02.021. Epub 2005 Apr 18. J Theor Biol. 2005. PMID: 16005305
The Vitti model employs the rate:state formalism and describes phosphorus (P) flow between four pools representing P content in gut, blood, bone and soft tissue in growing goats. ...The pigs maintained their P homeostasis in blood by regulation of P ex …
The Vitti model employs the rate:state formalism and describes phosphorus (P) flow between four pools representing P content i …
Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever.
Kotliar D, Raju S, Tabrizi S, Odia I, Goba A, Momoh M, Sandi JD, Nair P, Phelan E, Tariyal R, Eromon PE, Mehta S, Robles-Sikisaka R, Siddle KJ, Stremlau M, Jalloh S, Gire SK, Winnicki S, Chak B, Schaffner SF, Pauthner M, Karlsson EK, Chapin SR, Kennedy SG, Branco LM, Kanneh L, Vitti JJ, Broodie N, Gladden-Young A, Omoniwa O, Jiang PP, Yozwiak N, Heuklom S, Moses LM, Akpede GO, Asogun DA, Rubins K, Kales S, Happi AN, Iruolagbe CO, Dic-Ijiewere M, Iraoyah K, Osazuwa OO, Okonkwo AK, Kunz S, McCormick JB, Khan SH, Honko AN, Lander ES, Oldstone MBA, Hensley L, Folarin OA, Okogbenin SA, Günther S, Ollila HM, Tewhey R, Okokhere PO, Schieffelin JS, Andersen KG, Reilly SK, Grant DS, Garry RF, Barnes KG, Happi CT, Sabeti PC. Kotliar D, et al. Among authors: vitti jj. Nat Microbiol. 2024 Mar;9(3):751-762. doi: 10.1038/s41564-023-01589-3. Epub 2024 Feb 7. Nat Microbiol. 2024. PMID: 38326571 Free PMC article.
228 results